Navigation Links
CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine

DURHAM, N.C., Oct. 22, 2013 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., and ILDONG Pharmaceutical Co., Ltd., announced today that they have entered into a distribution and supply agreement for Lasmiditan in South Korea and Southeast Asia.



Under the terms of the agreement, CoLucid will receive upfront and milestone payments in addition to consideration for product supply in exchange for exclusive rights to ILDONG for development and commercialization of Lasmiditan in the territory. ILDONG will be responsible for the costs and activities related to development and regulatory approvals in the territory and will also participate in key registration trials as part of the global development plan. 

"We are very happy to announce the collaboration with ILDONG.  We look forward to working together with such a strong partner to bring Lasmiditan to the market to meet the many unmet needs of migraine sufferers," said Thomas P. Mathers, CEO of CoLucid.

ILDONG Pharma Chairman and CEO, Jung-chi Lee, Ph.D., commented, "We expect CoLucid's innovative drug, Lasmiditan, to be successfully developed under our partnership and be subsequently well positioned to perform in the Korean market and Southeast Asia in the near future.  We are sure that this will provide us a further opportunity to strengthen the relationship between our two companies."


Lasmiditan has been designed to deliver efficacy in acute migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.  It selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Its novel chemical class and differentiated site and mechanism of action led to Lasmiditan's designation as a "ditan", a new drug class, by the INN.

CoLucid has successfully completed six clinical studies for Lasmiditan, including a Phase 2b study treating a single migraine attack in 391 patients, as well as a TQTc study.

Phase 3 development will address two major unmet needs in patients who are poorly served by currently available therapies:

  • Patients with risk factors for cardiovascular disease and those with cardiovascular disease
  • Patients who have not had adequate response to triptans


Migraine is ranked as the seventh highest cause of global disability and in the top 10 causes of disability in 14 of 21 world regions studied, according to findings by the Global Burden of Disease Survey 2010 conducted by the World Health Organization. It is the leading cause of disability among neurological disorders.  Some 36 million Americans have migraine, more than have asthma or diabetes combined.  Migraine can be extremely disabling and costly, accounting for more than $20 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in the United States. The prevalence of migraine in Asia is approximately 9%, and in South Korea alone, it is 6%.  According to statistics available from the Health and Insurance Review Agency (HIRA), in 2012 more than 500,000 patients were diagnosed with migraine in Korea, with women accounting for 72% of these numbers.


CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes Lasmiditan, a novel treatment for migraine headache. Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans.  Lasmiditan is a member of a novel drug class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor receptors on peripheral blood vessels which are activated by triptans. For more information, please visit CoLucid at


ILDONG Pharmaceutical Co., Ltd., based in Seoul, Korea, is a leading Korean company focused on the development, manufacturing and marketing of pharmaceuticals and OTC products with sales of $317 million in 2012.  ILDONG, founded in 1941, is known to have leading expertise in various therapeutic categories, including neurology, antibiotics, gastrointestinal, anti-diabetics, cardiovascular and oncology.  For more information, visit ILDONG's website at

SOURCE CoLucid Pharmaceuticals, Inc; ILDONG Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
(Date:11/30/2015)... 30, 2015   VolitionRx Limited (NYSE MKT: VNRX), ... for a broad range of cancer types and other conditions, ... Conference, which will be held December 1 - 3 in in ... will be David Kratochvil , Chief Financial Officer and ... Relations. ® blood-based tests for colorectal cancer ...
(Date:11/30/2015)... LONDON , November 30, 2015 Mexico ... Healthcare and Life Sciences Report 2015 . --> Pharmaboardroom ... 2015 . Latin America , a country ... , a country of over 122 million people. --> ... in healthcare, pharmaceuticals, or life sciences insights into the second largest ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The Progressive Dental ... on January 29 and 30, 2016. The course welcomes dental professionals and members ... to learn how to better succeed in the modern dental marketplace. The course ...
(Date:11/30/2015)... ... , ... A record crowd gathered at the Pennsylvania Biotech Center of Bucks ... Blumberg Institute. , The institute, which is the research arm of the Hepatitis B ... the conference, which focused on ways companies can work to reduce the cost and ...
(Date:11/30/2015)... ... 30, 2015 , ... HemoTreat™ has announced that the company ... to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s Chief ... comparison chart and ingredient list allows our customers to quickly see why, and ...
(Date:11/30/2015)... ... November 30, 2015 , ... ChiliPad ... looking to maximize recovery through quality sleep. Tim DiFrancesco, training coach for the ... better night’s sleep. ChiliPad precisely regulates the surface temperature of each side of ...
(Date:11/30/2015)... ... November 30, 2015 , ... Advocare ... centered orthopedic care. Led by John Vitolo, M.D., the center offers their ... the team at Advocare Orthopedic & Sports Medicine is ready to help their ...
Breaking Medicine News(10 mins):